African Ancestry Genomic Psychiatry Cohort

 描述(由申请人提供)：非洲血统-基因组精神病学队列(AA-GPC)将支持基因组精神病学队列(GPC)的大规模扩展(目前n=33,000)，以扩大对非洲血统(AA)精神分裂症患者和对照的收集和基因组分析。GPC是一个庞大的临床队列，包括精神分裂症患者(n=10,000)，双相情感障碍患者(n=5,000)，家庭成员(n=3,000)，以及没有精神分裂症或双相情感障碍病史或家族史的对照参与者(n=15,000)(Pato，2013)。GPC成功招募了近6,000名再生障碍性贫血研究参与者(3,000名精神分裂症患者和3,000名对照组)，这支持了GPC网络在非裔美国人社区的登记能力。我们通过这个项目的目标是将AA精神分裂症队列增加到22,000名研究参与者(11,000名AA精神分裂症患者和11,000名AA对照)，并利用这些人的基因组来增加我们对基因对精神分裂症影响的理解。更具体地说：1)我们将通过招募另外5817名患者和6708名对照参与者，为18525名再生障碍性贫血参与者-8817名精神分裂症患者和9708名对照-创建一个总体GPC队列。现有的NIMH AA样本(2,183例和1,292例对照)将在现有同意和生物样本供应允许的范围内增加。总体而言，需要进行基因组特征鉴定的AA样本的最大数量为22,000个。2)我们将研究这一庞大的非洲血统精神分裂症队列中的基因组变异-使用外显子组测序、定制阵列分析和全基因组测序的战略组合-以拓宽和加深我们对影响精神分裂症风险的遗传变异的理解。与我们目前在这一领域的努力一样，博德研究所斯坦利精神病学研究中心的慈善基金将扩大NIMH的投资。

 DESCRIPTION (provided by applicant): The African Ancestry-Genomic Psychiatry Cohort (AA-GPC), will support a large expansion of the Genomic Psychiatry Cohort (GPC) (current n=33,000) that expands the collection and genomic analysis of patients suffering with schizophrenia and controls with African ancestry (AA). The GPC is a large clinical cohort of patients with schizophrenia (n=10,000), patients with bipolar disorder (n=5,000), family members (n=3,000), and control participants with no history or family history of schizophrenia or bipolar disorder (n=15,000) (Pato, 2013). The GPC's successful enrollment of nearly 6,000 AA research participants (3,000 suffering from schizophrenia and 3,000 controls) supports the enrollment capacity of the GPC network in African American communities. Our objective through this project is to increase AA schizophrenia cohorts to 22,000 research participants (11,000 AA patients suffering from schizophrenia and 11,000 AA controls), and to draw upon the genomes of these individuals to increase our understanding of genetic influences on schizophrenia. More specifically: 1) We will create an overall GPC cohort for the field of 18,525 AA participants - 8,817 suffering from schizophrenia and 9,708 controls - by enrolling an additional 5,817 patients and 6,708 control participants. Existing NIMH AA samples (2,183 cases and 1,292 controls) will be added to the extent allowed under existing consents and availability of bio-samples. In total, the maximum number of AA samples to be genomically characterized is 22,000. 2) We will study genome variation in this large African-ancestry schizophrenia cohort - using a strategic combination of exome sequencing, custom array analysis, and whole genome sequencing - to both broaden and deepen our understanding of genetic variation that influences risk of schizophrenia. As with our current efforts in this area, NIMH investment will be amplified by a contribution of philanthropic funds from the Broad Institute's Stanley Center for Psychiatric Research.